Phase III neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER positive postmenopausal early breast cancer.

EudraCT number 2006-000436-27

Study number BR3031

Status Closed

Opened August 2007

Expected recruitment duration 7 Years

A randomised, phase III, bifactorial clinical trial for ER positive postmenopausal early breast cancer to determine whether the addition of a COX 2 inhibitor to a 16 week treatment regimen of pre-operative exemestane or letrozole results in greater clinical response, with acceptable toxicity, than an aromatase inhibitor alone; and to determine whether exemestane provides greater objective clinical response than letrozole in the neoadjuvant setting.

For general enquires about the trial please email

NEO-EXCEL is an NCRN adopted trial.

Trial Documents 

A link to the current trial protocol is provided below. If there has been a recent amendment to the trial please ensure you have R&D approval for this specific version of the protocol before using as a reference.

More Information 

The NEO-EXCEL trial results can be found on the Cancer Research UK website.